Reference standard curves for <i>P</i>. <i>falciparum</i> 3D7 strain showing the relationship between parasitaemia and Ct / DNA concentration. by Daniel J. Bridges (12050007)

Standard curves for dilution series of hyper-immune CP3 sera for representative long-term (AMA-1) and short-term (Hyp2) <i>P</i>. <i>falciparum</i> antigens across all plates. by Daniel J. Bridges (12050007)

mTORC1 hyperactivation led to a decreased autophagic activity in the podocytes. by Wakiko Iwata (8600457)

“…Results are expressed as means ± s.d. *<i>P</i> < 0.05 compared with age-matched controls.…”

Two-way ANOVA table for Fig 3B. by Huiying Wu (1587136)

Two-way ANOVA table for Fig 6B. by Huiying Wu (1587136)

Overall outcomes for simulated intervention by country. by Aditya Kannan (12368567)

Microsimulation concept model. by Aditya Kannan (12368567)

Cost-effectiveness of intervention scale-up by country. by Aditya Kannan (12368567)

The effect of skeletal muscle Acsl1 partial ablation on the protein and gene expression of ACSL1 and muscular concentration of acyl-CoAs. by Kamila Roszczyc-Owsiejczuk (10322705)

Flowchart of the inclusion and exclusion criteria. by Toru Hosokawa (364158)

OF analysis of at 11–13 months of age (middle-aged). by Huiying Wu (1587136)

EZM analysis of at 11–13 months of age (middle aged). by Huiying Wu (1587136)

Immobility time of NrbKO and SpKO mice in the forced swim test (FST) at 3–5 months of age (young adult). by Huiying Wu (1587136)

Expression of neurabin and spinophilin in the mouse brain at 4 and 12 months of age. by Huiying Wu (1587136)

Open-field (OF) analysis of mice at 3–5 months of age (young adult). by Huiying Wu (1587136)

Immobility time of NrbKO and SpKO mice in FST at 11–13 months of age (middle-aged). by Huiying Wu (1587136)

Elevated zero maze (EZM) analysis of mice at 3–5 months of age (young adult). by Huiying Wu (1587136)

Numerical calculation process. by Liewang Qiu (18017814)

Results of the descriptive statistics for continuous variables. by Nuru Mohammed Hussen (13989547)

Baseline characteristics of patients. by Seydou Goro (17847203)

“…Using the number of competitors per distance method, our study showed that a “highly competitive” and “moderately competitive” markets decreased mortality by 31% [OR: 0.69 (0.59, 0.80); p<0.001] and by 12% respectively [OR: 0.88 (0.79, 0.99); p<0.03], compared to the “non-competitive” market. …”